4-(3-((4-(2-Methyl-1H-Imidaz-1-yl)Phenyl)Sulfanyl)Phenyl)Tetrahydro-2H-Pyran-4-Carboxamide, better known as CJ13610, is an orally active inhibitor of 5-lipoxygenase. Originally discovered by deCode Genetics, and later developed by Pfizer, CJ13610 has shown promise in preclinical models for pain. The compound was investigated in phase II clinical trials for asthma and chronic obstructive pulmonary disease; however, these efforts have been discontinued.

Olmesartan Lactone Impurity (Olmesartan EP Impurity B) is a cyclic ester impurity in commercial preparations of olmesartan medoxomil. Olmesartan medoxomil is an angiotensin II receptor antagonist, which is indicated for the treatment of hypertension.